Vivos Therapeutics logo
Vivos Therapeutics VVOS
$ 2.93 1.38%

Quarterly report 2024-Q3
added 11-14-2024

report update icon

Vivos Therapeutics Balance Sheet 2011-2024 | VVOS

Annual Balance Sheet Vivos Therapeutics

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

31 K -1.11 M -22.5 M -16.9 M 3.24 M -568 K - - - - - - -

Long Term Debt

1.2 M 1.99 M 298 K 423 K - 525 K - - - - - - -

Long Term Debt Current

474 K 419 K 1.26 M 867 K - - - - - - - - -

Total Non Current Liabilities

- - - 587 K 1.4 M 1.22 M - - - - - - -

Total Current Liabilities

7.29 M 6.81 M 7.51 M 7.82 M - - - - - - - - -

Total Liabilities

10.3 M 8.92 M 8.15 M 8.41 M 10.5 M 3.38 M - - - - - - -

Deferred Revenue

2.1 M 2.93 M 2.4 M 2.94 M 2.95 M 890 K - - - - - - -

Retained Earnings

-93.1 M -79.5 M -55.6 M -35.3 M -23.3 M -12.5 M - - - - - - -

Total Assets

10.7 M 13.7 M 33.7 M 25.3 M 7.55 M 8.2 M - - - - - - -

Cash and Cash Equivalents

1.64 M 3.52 M 24 M 18.2 M - - - - - - - - -

Book Value

411 K 4.8 M 25.5 M 16.9 M -2.94 M 4.83 M - - - - - - -

Total Shareholders Equity

411 K 4.8 M 25.5 M 16.9 M -2.94 M - - - - - - - -

All numbers in USD currency

Quarterly Balance Sheet Vivos Therapeutics

2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

1.2 M 1.2 M 1.4 M 1.2 M 1.2 M 1.2 M - 1.99 M 2.4 M 2.52 M 1.85 M 641 K 1.27 M 641 K 106 K 423 K 423 K 423 K 423 K 3.71 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

7.68 M 9.5 M 11.2 M 10.3 M 10.3 M 11.6 M - 8.92 M 8.54 M 9.54 M 8.7 M 8.15 M 8.56 M 8.15 M 7.61 M 8.41 M 8.41 M 8.41 M 8.41 M 9.18 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Deferred Revenue

1.3 M 1.8 M 2.4 M 2.14 M 2.4 M 2.4 M - 2.93 M 2.4 M 2.1 M 2.34 M 2.4 M 3.7 M 2.4 M 2.8 M 2.94 M 2.94 M 2.94 M 2.94 M 2.95 M - - - 890 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-101 M -98.7 M -96.8 M -93.1 M -88.8 M -86.7 M - -79.5 M -73.4 M -67.9 M -61.1 M -55.6 M -48.2 M -55.6 M -38.7 M -35.3 M -35.3 M -35.3 M -35.3 M -23.3 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

15.3 M 15.8 M 11.8 M 10.7 M 10.3 M 13.7 M - 13.7 M 18.4 M 24.4 M 29.6 M 33.7 M 41 M 33.7 M 22 M 25.3 M 25.3 M 25.3 M 25.3 M 7.55 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

6.31 M 6.9 M 2.61 M 1.64 M 988 K 3.94 M 200 K 3.52 M 6.72 M 12.7 M 17.8 M 24 M 28.5 M 24 M 14.1 M 18.2 M 18.2 M 18.2 M 18.2 M 469 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Book Value

7.66 M 6.35 M 582 K 411 K 46 K 2.11 M - 4.8 M 9.86 M 14.8 M 20.9 M 25.5 M 32.5 M 25.5 M 14.3 M 16.9 M 16.9 M 16.9 M 16.9 M -1.63 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

7.66 M 6.35 M 582 K 411 K 46 K 2.11 M 6.99 M 4.8 M 9.86 M 14.8 M 21 M 25.5 M 32.5 M 25.5 M 14.3 M 25.6 M 16.9 M 16.9 M 16.9 M -2.94 M - - - 4.83 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency